The ASH Annual Meeting is hosted by the American Society of Hematology. The conference offers individuals in the hematology space scientific programs, educational programs, special-interest sessions, and sessions on diversity, equity, and inclusion.

Videos

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses next steps in the research assessing zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.

Next Steps in Assessing BOVen Therapy in Patients With Previously Untreated CLL

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses trial results showing the safety and efficacy of zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.

Safety, Efficacy of BOVen Therapy in Patients With Previously Untreated CLL

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses the adverse events experienced by patients with previously untreated chronic lymphocytic leukemia when treated with zanubrutinib, obinutuzumab, and venetoclax.

Assessing Adverse Events From BOVen Therapy in Patients With Previously Untreated CLL

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, addresses the primary endpoint in the trial assessing zanubrutinib, obinutuzumab, and venetoclax in previously untreated chronic lymphocytic leukemia.

Assessing Primary Endpoint Trial Results for BOVen Therapy in Previously Untreated CLL

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses minimum residual disease-driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax in previously untreated chronic lymphocytic leukemia.

Assessing Zanubrutinib, Obinutuzumab, Venetoclax for Previously Untreated CLL

Articles

However, active disease alone for hospitalized patients was not associated with greater odds of dying from COVID-19, nor was receiving ongoing cancer treatment.

Certain Patients With Myelodysplastic Syndromes, Acute Leukemia at Higher Risk of Severe COVID-19 Illness

Data from a couple of new molecules could be encouraging for the treatment of acute myeloid leukemia and diffuse large B-cell lymphoma

New Molecules, Preclinical Data Show Promise for Treatment of AML, DLBCL

In addition to data showing the durable efficacy of acalabrutinib, other data presented at ASH 2021 demonstrate that the new tablet formulation of the drug supports ease of use for patients

Expert: Totality of Current Data Support the Use of Acalabrutinib in Patients With CLL

Emicizumab-kxwh demonstrated a favorable safety profile and effective bleed control in people with mild or moderate hemophilia A without factor VIII inhibitors.

Hemlibra Demonstrates Efficacy, Safety in Patients With Mild, Moderate Hemophilia A

Study results show that clonal hematopoiesis of indeterminate potential is associated with a lower likelihood of developing AD.